10.6084/m9.figshare.5242093.v1
Gevorgyan A.
Gevorgyan
A.
Bregni G.
Bregni
G.
Galli G.
Galli
G.
Zanardi E.
Zanardi
E.
de Braud F.
de Braud F.
Di Cosimo S.
Di Cosimo S.
Erratum: HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature
Karger Publishers
2017
Neuroendocrine carcinoma
Trastuzumab
Breast carcinoma
2017-07-25 14:09:06
Dataset
https://karger.figshare.com/articles/dataset/Erratum_HER2-Positive_Neuroendocrine_Breast_Cancer_Case_Report_and_Review_of_Literature/5242093
<b><i>Background:</i></b> Neuroendocrine carcinoma is an uncommon histology for breast cancer. <b><i>Case Report:</i></b> Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.